D 519927
Latest Information Update: 28 Dec 2000
Price :
$50 *
At a glance
- Originator Daiichi Pharmaceutical
- Class Antiulcers
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peptic ulcer
Most Recent Events
- 28 Dec 2000 Discontinued-Preclinical for Peptic ulcer in Japan (Unknown route)
- 09 Oct 1997 New profile
- 09 Oct 1997 Preclinical development for Peptic ulcer in Japan (Unknown route)